Castle Hook Partners LP Has $24.80 Million Position in Catalent, Inc. (NYSE:CTLT)

Castle Hook Partners LP lowered its stake in Catalent, Inc. (NYSE:CTLT) by 50.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 409,419 shares of the company’s stock after selling 422,018 shares during the period. Catalent accounts for 0.5% of Castle Hook Partners LP’s portfolio, making the stock its 29th largest position. Castle Hook Partners LP’s holdings in Catalent were worth $24,799,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after purchasing an additional 14,373 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Catalent by 289.8% in the third quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock valued at $2,986,000 after purchasing an additional 36,652 shares in the last quarter. Swedbank AB acquired a new stake in shares of Catalent in the first quarter valued at approximately $1,659,000. New York Life Investment Management LLC increased its holdings in shares of Catalent by 67.9% in the second quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock valued at $16,751,000 after purchasing an additional 120,502 shares in the last quarter. Finally, Van ECK Associates Corp boosted its stake in Catalent by 47.4% in the third quarter. Van ECK Associates Corp now owns 124,424 shares of the company’s stock valued at $7,391,000 after acquiring an additional 39,983 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Friday, November 22nd. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Trading Up 0.4 %

Shares of NYSE CTLT opened at $61.00 on Thursday. The company’s fifty day moving average is $59.86 and its 200-day moving average is $58.41. The stock has a market cap of $11.07 billion, a price-to-earnings ratio of -26.99, a P/E/G ratio of 2.44 and a beta of 1.16. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $61.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) earnings per share. Equities research analysts predict that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Transactions at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.